• Tapering TNFi dose by 33% did not affect RA flares

    6 days ago - By Healio

    In patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors, dose tapering by 33% did not appear to diminish clinical response and appeared to be a reasonable option for patients in sustained remission, according to findings from the OPTTIRA trial. Researchers evaluated patients with rheumatoid arthritis and who achieved favorable responses, including low disease activity or remission, from treatment with tumor necrosis factor inhibitor medications at standard doses and one or more disease-modifying antirheumatic drugs. Sustained good responses were defined as DAS28...
    Read more ...